According to a study in the journal Cancer, without the use of PSA screening the number of men presenting with cases of metastatic prostate cancer would be three times greater than the actual number observed today.
The addition of the multi-tyrosine kinase inhibitor sorafenib to a gemcitabine/cisplatin regimen failed to improve overall survival among patients with advanced nonsquamous non-small-cell lung cancer, according to a new randomized phase III trial.
The FDA has approved aflibercept (Zaltrap) to be used with the chemotherapy regimen FOLFIRI in the treatment of adults with metastatic colorectal cancer.
A new study finds that baseline testing for HPV can better predict long-term negative cervical cancer outcomes compared to a Pap smear.
Results from a trial of a new therapeutic vaccine for renal cell carcinoma demonstrate that those patients with a measurable immune response to the vaccine have a prolonged overall survival.
A new study suggests suppression of breast cancer metastasis relies on an antitumor immune response. Researchers found that administering interferon can reduce bone metastases and increase the survival time of a metastatic breast cancer mouse model.
Last week the US Food and Drug Administration approved carfilzomib (Kyprolis) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib (Velcade) and an immunomodulatory therapy.
A new target of melanoma tumors has been identified that may be promising as part of a novel combination therapy for melanoma. In a study published in Nature Medicine, researchers have identified that more than half of melanoma cases, both early and late-stage, may have higher levels of MDM4, a p53-interacting protein.
The FDA approved the mTOR inhibitor everolimus (Afinitor) last week for use in postmenopausal women with HER2-negative, hormone-receptor-positive advanced breast cancer patients.
Three-year results from the ENESTnd trial show continued superiority of nilotinib over imatinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase, according to a new paper published online ahead of print in Leukemia in June.